Suppr超能文献

利用 FDA 的 Sentinel 系统的功能来改善肾脏护理。

Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care.

机构信息

Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts

Department of Pharmacy, Mayo Clinic, Rochester, Minnesota.

出版信息

J Am Soc Nephrol. 2020 Nov;31(11):2506-2516. doi: 10.1681/ASN.2020040526. Epub 2020 Oct 19.

Abstract

The Sentinel System is a national electronic postmarketing resource established by the US Food and Drug Administration to support assessment of the safety and effectiveness of marketed medical products. It has built a large, multi-institutional, distributed data network that contains comprehensive electronic health data, covering about 700 million person-years of longitudinal observation time nationwide. With its sophisticated infrastructure and a large selection of flexible analytic tools, the Sentinel System permits rapid and secure analyses, while preserving patient privacy and health-system autonomy. The Sentinel System also offers enhanced capabilities, including accessing full-text medical records, supporting randomized clinical trials embedded in healthcare delivery systems, and facilitating effective collection of patient-reported data using mobile devices, among many other research programs. The nephrology research community can use the infrastructure, tools, and data that this national resource offers for evidence generation. This review summarizes the Sentinel System and its ability to rapidly generate high-quality, real-world evidence; discusses the program's experience in, and potential for, addressing gaps in kidney care; and outlines avenues for conducting research, leveraging this national resource in collaboration with Sentinel investigators.

摘要

Sentinel 系统是美国食品和药物管理局建立的一个国家电子上市后资源,用于支持对已上市医疗产品的安全性和有效性进行评估。它构建了一个大型的、多机构的、分布式的数据网络,其中包含全面的电子健康数据,涵盖了全国约 7 亿人的纵向观察时间。凭借其复杂的基础设施和大量灵活的分析工具,Sentinel 系统允许快速、安全地进行分析,同时保护患者隐私和医疗系统的自主权。Sentinel 系统还提供了增强的功能,包括访问全文医疗记录、支持在医疗保健系统中嵌入的随机临床试验,以及使用移动设备有效收集患者报告的数据,以及许多其他研究计划。肾脏病学研究界可以利用这个国家资源提供的基础设施、工具和数据来生成证据。这篇综述总结了 Sentinel 系统及其快速生成高质量、真实世界证据的能力;讨论了该计划在解决肾脏护理方面差距的经验和潜力;并概述了利用 Sentinel 调查人员合作开展研究、利用这一国家资源的途径。

相似文献

1
Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care.
J Am Soc Nephrol. 2020 Nov;31(11):2506-2516. doi: 10.1681/ASN.2020040526. Epub 2020 Oct 19.
2
The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:1-8. doi: 10.1002/pds.2343.
3
A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System.
Pharmacoepidemiol Drug Saf. 2021 Jul;30(7):827-837. doi: 10.1002/pds.5240. Epub 2021 Apr 18.
4
The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
Clin Pharmacol Ther. 2016 Mar;99(3):265-8. doi: 10.1002/cpt.320. Epub 2016 Jan 12.
10
Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.
Vaccine. 2013 Dec 30;31 Suppl 10:K98-112. doi: 10.1016/j.vaccine.2013.04.088.

引用本文的文献

2
Drug stewardship in chronic kidney disease to achieve effective and safe medication use.
Nat Rev Nephrol. 2024 Jun;20(6):386-401. doi: 10.1038/s41581-024-00823-3. Epub 2024 Mar 15.
3
Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryption.
Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2304415120. doi: 10.1073/pnas.2304415120. Epub 2023 Aug 7.
4
The US Food and Drug Administration Sentinel System: a national resource for a learning health system.
J Am Med Inform Assoc. 2022 Nov 14;29(12):2191-2200. doi: 10.1093/jamia/ocac153.
5
A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants.
Pharmacoepidemiol Drug Saf. 2022 Nov;31(11):1164-1173. doi: 10.1002/pds.5514. Epub 2022 Aug 15.
7
Big Data in Nephrology.
Nat Rev Nephrol. 2021 Oct;17(10):676-687. doi: 10.1038/s41581-021-00439-x. Epub 2021 Jun 30.

本文引用的文献

2
Studying Medication Safety in Pregnancy: A Call for New Approaches, Resources, and Collaborations.
Pediatrics. 2020 Jul;146(1). doi: 10.1542/peds.2020-1540. Epub 2020 Jun 8.
3
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
Nephrol Dial Transplant. 2020 Jan 1;35(Suppl 1):i48-i55. doi: 10.1093/ndt/gfz252.
4
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
J Am Soc Nephrol. 2020 Feb;31(2):435-446. doi: 10.1681/ASN.2019070676. Epub 2020 Jan 2.
6
Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018.
PLoS One. 2019 Dec 5;14(12):e0223515. doi: 10.1371/journal.pone.0223515. eCollection 2019.
7
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1692-1700. doi: 10.2215/CJN.00990119. Epub 2019 Oct 31.
9
Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Diabetes Care. 2020 Jan;43(1):90-97. doi: 10.2337/dc19-1481. Epub 2019 Oct 10.
10
Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
Support Care Cancer. 2020 Jun;28(6):2553-2562. doi: 10.1007/s00520-019-05063-x. Epub 2019 Sep 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验